salazosulfapyridine enteric coated tablets 250mg "ch" (サラゾスルファピリジン腸溶錠250mg「ch」)
nihon generic co.,ltd - salazosulfapyridine - yellow to yellowish brown tablet, diameter: 9.7 mm, thickness: 5.0 mm
salazosulfapyridine enteric coated tablets 500mg "ch" (サラゾスルファピリジン腸溶錠500mg「ch」)
nihon generic co.,ltd - salazosulfapyridine - yellow to yellowish brown tablet, major axis: 18.3 mm, minor axis: 9.8 mm, thickness: 5.2 mm
salazosulfapyridine tablet 500mg "nichiiko" (サラゾスルファピリジン錠500mg「日医工」)
nichi-iko pharmaceutical co.,ltd - salazosulfapyridine - yellow to yellow-brown tablet, major axis: approx. 17.2 mm, minor axis: approx. 7.1 mm, thickness: approx. 5.7 mm
salazosulfapyridine tablets 500mg "jg" (サラゾスルファピリジン錠500mg「jg」)
nihon generic co.,ltd - salazosulfapyridine - brownish-red tablet, diameter: 11.0 mm, thickness: 5.1 mm
sulfapyridine 250mg capsules
special order - sulfapyridine - oral capsule - 250mg
salazopyrin en-tablet 500 mg
pfizer private limited - sulphasalazine - enteric coated tablet - 500 mg - sulphasalazine 500 mg
dagenan tab 500mg tablet
aventis pharma inc - sulfapyridine - tablet - 500mg - sulfapyridine 500mg - sulfonamides
azulfidine en-tabs- sulfasalazine tablet, delayed release
pfizer laboratories div pfizer inc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - azulfidine en-tabs tablets are indicated: azulfidine en-tabs is particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. in patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. unlike anti-inflammatory drugs, azulfidine en-tabs does not produce an immediate response. concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of azulfidine en-tabs is apparent. azulfidine en-tabs tablets are contraindicated in: hypersensitivity to sulfasalazine, its metabolites, sulfonam
sulfasalazine tablet, delayed release
greenstone llc - sulfasalazine (unii: 3xc8guz6cb) (sulfasalazine - unii:3xc8guz6cb) - sulfasalazine 500 mg - sulfasalazine delayed release tablets are indicated: sulfasalazine delayed release tablets are particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. in patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. unlike anti-inflammatory drugs, sulfasalazine delayed release tablets do not produce an immediate response. concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of sulfasalazine delayed release tablets is apparent. sulfasalazine delayed release tablets are con
azulfidine en tablets 250mg (アザルフィジンen錠250mg)
ayumi pharmaceutical co., ltd. - salazosulfapyridine - yellow to yellowish brown tablet, major axis: 12.8 mm, minor axis: 6.8 mm